Opinion|Videos|July 22, 2024

Real-World Data for Risdiplam in Adult Patients with Spinal Muscular Atrophy

Panelists examine the available real-world data (RWD) on the use of risdiplam in adult patients with spinal muscular atrophy (SMA) from various studies conducted worldwide, discussing its potential efficacy and safety as a treatment option for adult SMA patients.

  1. Discuss real-world evidence for risdiplam in adult patients.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Latest CME